癌/睾丸抗原 (CTA) 是一个由 100 个以上蛋白组成的家族，其正常表达在很大程度上限于睾丸、卵巢的免疫赦免生殖细胞和胎盘滋养层细胞。虽然大多数正常体细胞组织都缺乏 CTA 表达，但由于基因表达的表观遗传沉默，因此它们在许多人实体和液体肿瘤细胞中的表达上调 (1,2)。就其本身而言，CTA 是各种选择性发作肿瘤的免疫治疗方法的一个有吸引力的靶标，因此受到了广泛关注 (3)。

Melanoma-associated antigen-C2/Cancer testis antigen 10 (MAGE-C2/CT10) belongs to the type I MAGE family of proteins. In normal human tissues, MAGE-C2/CT10 expression is nuclear and largely restricted to germline cells of the testis (4). At the molecular level, research studies have demonstrated that MAGE-C2/CT10 physically interacts with and enhances activity of the TRIM28 E3 RING ubiquitin ligase (5,6). MAGE-C2/CT10 has also been shown to interact with and regulate the activity of SCF CRL E3 ubiquitin ligase complexes toward substrates that control cell cycle progression, suggesting a role for MAGE-C2/CT10 in malignant transformation (7). Indeed, MAGE-C2/CT10 is aberrantly expressed in testicular germ cell tumors, prostate carcinoma, hepatocellular carcinoma, and melanoma (8-11). Furthermore, MAGE-C2/CT10 is immunogenic in some tumor types and as a result, there is interest in targeting antigenic epitopes presented in the context of class I MHC alleles using engineered TCRs (12,13).